Jeppson Wealth Management LLC Decreases Stock Position in Eli Lilly and Company (NYSE:LLY)

Jeppson Wealth Management LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,253 shares of the company’s stock after selling 100 shares during the quarter. Eli Lilly and Company makes up 1.5% of Jeppson Wealth Management LLC’s investment portfolio, making the stock its 12th biggest holding. Jeppson Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Algert Global LLC boosted its position in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company’s stock worth $456,000 after acquiring an additional 110 shares in the last quarter. RiverFront Investment Group LLC acquired a new position in Eli Lilly and Company in the second quarter valued at approximately $256,000. Anchor Investment Management LLC increased its stake in Eli Lilly and Company by 0.9% in the second quarter. Anchor Investment Management LLC now owns 13,966 shares of the company’s stock valued at $12,645,000 after purchasing an additional 131 shares during the last quarter. Centaurus Financial Inc. lifted its position in shares of Eli Lilly and Company by 102.4% during the 2nd quarter. Centaurus Financial Inc. now owns 6,099 shares of the company’s stock worth $5,522,000 after buying an additional 3,085 shares during the last quarter. Finally, Greater Midwest Financial Group LLC boosted its holdings in shares of Eli Lilly and Company by 230.2% in the 2nd quarter. Greater Midwest Financial Group LLC now owns 4,018 shares of the company’s stock valued at $3,744,000 after buying an additional 2,801 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $823.59 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $781.85 billion, a price-to-earnings ratio of 89.04, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. The business’s 50 day simple moving average is $780.80 and its 200-day simple moving average is $845.98. Eli Lilly and Company has a 12 month low of $637.00 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has authorized a share buyback program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Citigroup cut their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Wells Fargo & Company decreased their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $997.22.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.